[Cl:1][C:2]1[CH:27]=[CH:26][C:5]2=[N:6][N:7]([CH2:9][C:10]3[C:18]4[C:13](=[N:14][CH:15]=[CH:16][CH:17]=4)[N:12](C(OC(C)(C)C)=O)[N:11]=3)[N:8]=[C:4]2[C:3]=1[O:28][C:29]1[CH:34]=[C:33]([Cl:35])[CH:32]=[C:31]([C:36]#[N:37])[C:30]=1[Cl:38]>C(O)(C(F)(F)F)=O>[Cl:38][C:30]1[C:29]([O:28][C:3]2[C:4]3[C:5](=[N:6][N:7]([CH2:9][C:10]4[C:18]5[C:13](=[N:14][CH:15]=[CH:16][CH:17]=5)[NH:12][N:11]=4)[N:8]=3)[CH:26]=[CH:27][C:2]=2[Cl:1])=[CH:34][C:33]([Cl:35])=[CH:32][C:31]=1[C:36]#[N:37]tert-butyl 3-{[5-chloro-4-(2,5-dichloro-3-cyanophenoxy)-2H-1,2,3-benzotriazol-2-yl]methyl}-1H-pyrazolo[3,4-b]pyridine-1-carboxylate (100 mg, 0.175 mmol) was dissolved in TFA (5 mL) at room temperature. After 20 minutes, the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/H2O+0.1% TFA. The product fractions were concentrated under reduced pressure to yield the title compound. 1H NMR (DMSO-d6) δ 13.80 (s, 1H), 8.44 (d, J=2.9 Hz, 1H), 7.99 (d, J=2.2 Hz), 7.95 (m, 1H), 7.93 (d, J=9.2 Hz, 1H), 7.62 (d, J=9.2 Hz, 1H), 7.35 (d, J=2.3 Hz, 1H), 7.16 (dd, J=8.0 Hz, J=4.6 Hz, 1H), 6.30 (s, 2H). HRMS (M+1)=470.0076.